Positive News SentimentPositive NewsNASDAQ:KNSA Kiniksa Pharmaceuticals (KNSA) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free KNSA Stock Alerts $19.73 -0.26 (-1.30%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$19.47▼$20.1350-Day Range$17.63▼$21.7452-Week Range$10.29▼$22.09Volume359,719 shsAverage Volume436,383 shsMarket Capitalization$1.39 billionP/E Ratio109.62Dividend YieldN/APrice Target$28.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Kiniksa Pharmaceuticals alerts: Email Address Kiniksa Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside41.9% Upside$28.00 Price TargetShort InterestBearish4.06% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$1.27 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.05) to ($0.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.30 out of 5 starsMedical Sector359th out of 939 stocksPharmaceutical Preparations Industry171st out of 444 stocks 3.5 Analyst's Opinion Consensus RatingKiniksa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.00, Kiniksa Pharmaceuticals has a forecasted upside of 41.9% from its current price of $19.73.Amount of Analyst CoverageKiniksa Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.06% of the outstanding shares of Kiniksa Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverKiniksa Pharmaceuticals has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Kiniksa Pharmaceuticals has recently increased by 3.24%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldKiniksa Pharmaceuticals does not currently pay a dividend.Dividend GrowthKiniksa Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KNSA. Previous Next 3.3 News and Social Media Coverage News SentimentKiniksa Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Kiniksa Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for KNSA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Kiniksa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kiniksa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,269,493.00 in company stock.Percentage Held by Insiders54.23% of the stock of Kiniksa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.95% of the stock of Kiniksa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Kiniksa Pharmaceuticals are expected to decrease in the coming year, from ($0.05) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kiniksa Pharmaceuticals is 109.62, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.21.Price to Earnings Ratio vs. SectorThe P/E ratio of Kiniksa Pharmaceuticals is 109.62, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 182.24.Price to Book Value per Share RatioKiniksa Pharmaceuticals has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Kiniksa Pharmaceuticals Stock (NASDAQ:KNSA)Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Read More KNSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KNSA Stock News HeadlinesMarch 16, 2024 | insidertrades.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sells 5,582 Shares of StockMarch 7, 2024 | msn.com5 Biotech Stocks With 26% Upside Potential or MoreMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 3, 2024 | investing.comEarnings call: Kiniksa Pharmaceuticals sees robust growth in ARCALYST salesMarch 3, 2024 | wsj.comKiniksa Pharmaceuticals Ltd.March 1, 2024 | seekingalpha.comKiniksa Pharmaceuticals Ltd. (KNSA) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comKiniksa Pharmaceuticals Full Year 2023 Earnings: Beats ExpectationsMarch 1, 2024 | finance.yahoo.comChief Medical Officer John Paolini Sells 10,156 Shares of Kiniksa Pharmaceuticals Ltd (KNSA)March 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.February 29, 2024 | finance.yahoo.comAre You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great ChoiceFebruary 29, 2024 | finance.yahoo.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: G1 Therapeutics (GTHX), Kiniksa Pharmaceuticals (KNSA)February 28, 2024 | finance.yahoo.comKiniksa Pharmaceuticals Ltd (KNSA) Reports Strong Revenue Growth in Q4 and Full-Year 2023February 28, 2024 | globenewswire.comKiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio ExecutionFebruary 28, 2024 | markets.businessinsider.comWhat Wall Street expects from Kiniksa Pharmaceuticals's earningsFebruary 21, 2024 | finance.yahoo.comKiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024February 21, 2024 | globenewswire.comKiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024February 12, 2024 | msn.comWall Street Analysts Predict a 38.07% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should KnowFebruary 12, 2024 | finance.yahoo.comKiniksa Pharmaceuticals, Ltd. (KNSA) is on the Move, Here's Why the Trend Could be SustainableFebruary 12, 2024 | finance.yahoo.comWall Street Analysts Predict a 38.07% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should KnowJanuary 31, 2024 | uk.finance.yahoo.comGSK (GSK) Misses Q4 Earnings EstimatesJanuary 23, 2024 | finance.yahoo.comHow Much Upside is Left in Kiniksa Pharmaceuticals, Ltd. (KNSA)? Wall Street Analysts Think 43.93%January 15, 2024 | finance.yahoo.comInvestors in Kiniksa Pharmaceuticals (NASDAQ:KNSA) have seen returns of 30% over the past yearJanuary 9, 2024 | msn.comIs Kiniksa Pharmaceuticals (KNSA) Stock a Solid Choice Right Now?January 5, 2024 | seekingalpha.comKiniksa Pharmaceuticals: Early 2024 Corporate Update A Mixed BagJanuary 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Rhythm Pharmaceuticals (RYTM) and Kiniksa Pharmaceuticals (KNSA)January 5, 2024 | markets.businessinsider.comStrong Arcalyst Sales and Promising Pipeline Reinforce Kiniksa Pharmaceuticals Buy RatingSee More Headlines Receive KNSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/29/2024Next Earnings (Estimated)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KNSA CUSIPN/A CIK1730430 Webwww.kiniksa.com Phone(781) 431-9100FaxN/AEmployees297Year FoundedN/APrice Target and Rating Average Stock Price Target$28.00 High Stock Price Target$28.00 Low Stock Price Target$28.00 Potential Upside/Downside+41.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.18 Trailing P/E Ratio109.62 Forward P/E RatioN/A P/E GrowthN/ANet Income$14.08 million Net Margins5.11% Pretax Margin-6.16% Return on Equity-6.12% Return on Assets-5.20% Debt Debt-to-Equity RatioN/A Current Ratio4.34 Quick Ratio3.85 Sales & Book Value Annual Sales$270.26 million Price / Sales5.15 Cash FlowN/A Price / Cash FlowN/A Book Value$6.23 per share Price / Book3.17Miscellaneous Outstanding Shares70,610,000Free Float32,320,000Market Cap$1.39 billion OptionableOptionable Beta0.28 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Sanj K. Patel (Age 55)CEO & Chairman of the Board Comp: $1.44MMr. Eben Tessari (Age 42)Senior VP & COO Comp: $643.75kDr. John F. Paolini (Age 59)Senior VP & Chief Medical Officer Comp: $753.7kMr. Mark Ragosa C.F.A. (Age 50)Senior VP & CFO Mr. Michael R. Megna CPA (Age 53)Chief Accounting Officer & Group VP of Finance Ms. Mei JangSenior VP of Technical OperationsRachel FrankAssociate Director of Investor RelationsMr. Chad MorinSVP, Chief Compliance Officer & Head of QualityMs. Madelyn Demsky Zeylikman (Age 50)SVP, General Counsel & Secretary Ms. Melissa MannoSenior VP & Chief Human Resources OfficerMore ExecutivesKey CompetitorsImmunomeNASDAQ:IMNMAkero TherapeuticsNASDAQ:AKROOcular TherapeutixNASDAQ:OCULDisc MedicineNASDAQ:IRONDay One BiopharmaceuticalsNASDAQ:DAWNView All CompetitorsInsiders & InstitutionsHealthcare of Ontario Pension Plan Trust FundSold 15,000 shares on 3/21/2024Ownership: 0.322%Vanguard Group Inc.Bought 6,342 shares on 3/11/2024Ownership: 4.200%Sanj K PatelSold 5,582 sharesTotal: $117,222.00 ($21.00/share)Sanj K PatelSold 12,742 sharesTotal: $273,825.58 ($21.49/share)Goldman Sachs Group Inc.Bought 43,430 shares on 3/1/2024Ownership: 1.293%View All Insider TransactionsView All Institutional Transactions KNSA Stock Analysis - Frequently Asked Questions Should I buy or sell Kiniksa Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" KNSA shares. View KNSA analyst ratings or view top-rated stocks. What is Kiniksa Pharmaceuticals' stock price target for 2024? 1 equities research analysts have issued 12-month target prices for Kiniksa Pharmaceuticals' shares. Their KNSA share price targets range from $28.00 to $28.00. On average, they expect the company's share price to reach $28.00 in the next twelve months. This suggests a possible upside of 41.9% from the stock's current price. View analysts price targets for KNSA or view top-rated stocks among Wall Street analysts. How have KNSA shares performed in 2024? Kiniksa Pharmaceuticals' stock was trading at $17.54 at the beginning of 2024. Since then, KNSA stock has increased by 12.5% and is now trading at $19.73. View the best growth stocks for 2024 here. When is Kiniksa Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our KNSA earnings forecast. How were Kiniksa Pharmaceuticals' earnings last quarter? Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced its quarterly earnings results on Wednesday, February, 28th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.15. The firm earned $83.40 million during the quarter, compared to the consensus estimate of $72.31 million. Kiniksa Pharmaceuticals had a net margin of 5.11% and a negative trailing twelve-month return on equity of 6.12%. What ETFs hold Kiniksa Pharmaceuticals' stock? ETFs with the largest weight of Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).ALPS Medical Breakthroughs ETF (SBIO). What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO? 1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Kiniksa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD). When did Kiniksa Pharmaceuticals IPO? Kiniksa Pharmaceuticals (KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Kiniksa Pharmaceuticals' major shareholders? Kiniksa Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.22%), Vanguard Group Inc. (4.20%), Rubric Capital Management LP (4.13%), Goldman Sachs Group Inc. (1.29%), Goldman Sachs Group Inc. (1.29%) and Granahan Investment Management LLC (1.03%). Insiders that own company stock include Barry D Quart, John F Paolini, Mark Ragosa, Michael R Megna and Sanj K Patel. View institutional ownership trends. How do I buy shares of Kiniksa Pharmaceuticals? Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KNSA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.